About Etrebelle®
Etrebelle® is Regenbogen’s signature injectable hybrid filler line, engineered to deliver both instant aesthetic improvements and long-term dermal regeneration. Its innovative HA + PLA composition offers versatility for aesthetic professionals seeking natural, progressive enhancements across a range of facial rejuvenation protocols. With dual concentration options, Etrebelle® provides tailored treatment flexibility, bridging the gap between traditional fillers and collagen biostimulators
Etrebelle® 200 mg/vial
Etrebelle® 200 mg/vial is the more concentrated variant within the Etrebelle® hybrid filler range, formulated by Regenbogen to address deeper facial volume deficiencies and more pronounced structural contouring needs. Containing the same innovative blend of cross-linked hyaluronic acid and PLA microparticles, this high-dose injectable delivers an immediate volumizing effect through HA while promoting significant neocollagenesis for sustained dermal regeneration. Etrebelle® 200 mg is specifically recommended for midface augmentation, cheek volumization, jawline refinement, and deep wrinkle correction, offering a long-lasting, natural enhancement as collagen production gradually improves skin density and firmness. The formulation is designed for smooth injectability and even particle dispersion, ensuring consistent clinical outcomes and a natural, progressive aesthetic improvement over time.
With CE certification and high-quality Korean manufacturing, Etrebelle® 200 mg positions itself as a reliable option for comprehensive facial rejuvenation protocols requiring both instant and regenerative effects.
Etrebelle® 50 mg/vial
Etrebelle® 50 mg/vial is a hybrid injectable dermal filler designed by Regenbogen Co., Ltd. in South Korea, combining cross-linked hyaluronic acid (HA) with poly-D, L-lactic acid (PLA) microparticles in a balanced formulation. This product is intended for subtle, natural enhancements, offering immediate hydration and volume restoration from the HA component while progressively stimulating collagen production through the controlled biodegradation of PLA particles. Its 50 mg concentration is particularly suitable for treating moderate facial lines, fine wrinkles, nasolabial folds, and early signs of volume loss. Etrebelle® 50 mg integrates smoothly into the dermal tissue, offering a gentle lifting effect and supporting dermal elasticity over several months. The product is CE-compliant, produced in GMP-certified facilities, and favored by aesthetic practitioners seeking gradual, regenerative results combined with an immediate, natural finish for delicate rejuvenation procedures.
About Regenbogen Co., Ltd
Regenbogen Co., Ltd., based in South Korea, is a specialized manufacturer in the field of aesthetic medicine, developing advanced cosmetic threads and hybrid injectable products. The company focuses on regenerative technologies, combining HA and PLA-based fillers under CE-compliant manufacturing standards. The Etrebelle® range is Regenbogen’s flagship injectable line, internationally recognized for its dual-action formulation and reliable safety profile.